1. Institute Outline
  2. Message
  3. Members
  4. History Museum of CIEA

Institute Outline

Name Central Institute for Experimental Animals (CIEA)
Address 3-25-12 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821 JAPAN
Mission Development of quality humanized animals with a stable reproduction level, and the research of human diseases and clarification of their causes through the use of laboratory animals as live measurement standards.
Founder & Founded 1952, Tatsuji Nomura, M.D., Ph.D.
Chairman of the Board
Chief Executive Officer
Ryuta Nomura
Research Director Jun-ichi Hata, M.D., Ph.D.

Message

理事長 野村龍太
Chairman Ryuta Nomura

Central Institute for Experimental Animals is private and independent Non-profit institute, founded in 1952 with the aim of contributing to medical care and medical science based on animal experiments, which are considered to be quite rare globally.

We have earned an excellent reputation in the research, development and commercialization of the world's most advanced laboratory animals and germ-free animal-related technologies that provide support therefor, as well as other technologies such as monitoring tests, pathology tests, genetic modification, developmental engineering, and image analysis, and cooperate with universities and research institutions in Japan and other countries, international public organizations such as WHO, NIH, FDA, and NIBSC, and business enterprises.

Working with WHO, we played a very important role and achieved satisfactory results in a polio eradication program, in the establishment of muscular dystrophy therapeutics, in the establishment of procedures to demonstrate the safety of regenerative and cellular medicine, and in the development of various pharmaceuticals for cancers and other diseases. We aim to do something others have never done, commercialize work that has been started even if it takes 20 to 30 years, and contribute to the health of human-beings of the world as a world-class system. We perform cutting-edge original research, collaborate with world-leading researchers, universities, business enterprises, and regulatory agents, and continue research and development activities to contribute to solving issues which the world today faces, such as cancers, life-threatening diseases of the central nervous system such as Alzheimer's disease, from rare diseases to familiar allergic diseases, and the development of fertility treatment technologies to address declining birthrate and aging population.

On the other hand, as an independent research institute, it is inevitable that we independently raise funds for our research. We need to expand the structure to commercialize the research outcomes by entering into licensing agreements with business enterprises, and collect royalties to fund further research. While being a research institute, there is a need for development activities not only for research but also for commercialization, diffusion and sales expansion activities in cooperation with licensees in Europe, the United States, China, and other countries, and a consulting business. This unique business model is our quintessence. We think that research outcomes become a public asset when they are applied in real-world settings and are widely used by people all over the world, contributing to the health of human-beings.

We, CIEA, always have a sense of tension, break the common sense, and keep challenging while keeping the essence in sight.

We would highly appreciate your continued support and cooperation.

Central Institute for Experimental Animals
Chairman Ryuta Nomura

所長 秦 順一
Research Director Jun-ichi Hata

Since 1952, Central Institute for Experimental Animals ( CIEA) has produced and supplied qualified laboratory animals for medical researches of academic organizations and drug discovery companies. The development of novel animal experiment methods using these animals, as well as advanced collaborative medical researches all over the world. Meanwhile, in view of the recent situation of drug discovery researches, 10% or less of candidate substances have been marketed as new drugs (according to the FDA), and much of research resources and efforts have been exhausted during research. It is said that the reason for this is the inconsistency of the POC between nonclinical and clinical studies, as the pharmacokinetic, efficacy, and safety assessment data obtained in laboratory animals are different from those in humans. Accordingly, CIEA has created various humanized animals using genetic modification technology to bring laboratory animals closer to humans. In addition, human disease models have been established using them, and some are even utilized for drug discovery research, as well as pathologic elucidation research in academic organizations. Furthermore, we succeeded in the creation of laboratory animal models and genetic modification of the marmoset, a small nonhuman primate species. For pathologic analysis of disease model animals, we have developed elucidation procedures using noninvasive methods such as MRI and CT in addition to conventional pathological analysis. In addition, we are monitoring animals including neuropsychiatric disease model animals for 24 hours a day by digitalizing behaviors, and jointly developing the evaluation method without inducing stress on the animals. These enable detailed elucidation of the progress of the lesion from the early stages of the disease.

Human diseases and disease models are of course extremely different. Accordingly, when evaluating disease model animals, it is necessary to adequately examine which part of the human disease they extrapolate and utilize them in research. At present, accumulation of big data on human diseases has substantially revealed their pathology from the primary lesion. Also utilizing such information, further improvement and development of disease model animals are necessary.

Thus, we will contribute continuously to the progression of medical science through animal experiments that use reproducible animals as much as possible.

Central Institute for Experimental Animals
Research Director Jun-ichi Hata

Members

Board members

Chairman of the Board Ryuta Nomura
Board member,
Research Director
Jun-ichi Hata, M.D., Ph.D.
Board member,
Vice Research Director
Mamoru Ito, D.V.M., Ph.D.
Board member Naoko Kagiyama, D.V.M., Ph.D, DJCLAM
Board member Mitsuhiko Kawai
Board member Akira Takakura, Ph.D.
Board member Tatsutoshi Nakahata, M.D., Ph.D.
Auditor Satoru Endo

Councillors

Councillor Hiroshi Nagata
Councillor Satoshi Yamamoto, M.D., Ph.D.
Councillor Osamu Nishimura, Ph.D.
Councillor Nobuyoshi Yamazaki

Members of Advisory Committee

Chair Sonoko Habu, M.D., Ph.D.
Member Minoru Ko, M.D., Ph.D.
Member Hitoshi Nakagama, M.D., D.M. Sc.
Member Katsuhiko Mikoshiba, M.D., Ph.D.
Member Yoshikuni Mizuno, M.D., Ph.D.
Member Tatsumi Yamazaki, Ph.D.
Member Kazuhiko Yamamoto, M.D., Ph.D.

History Museum of CIEA

This museum introduces the history of CIEA that extends to almost 70 years, together with various interesting events that have actually taken place over the decades.

PAGE TOP

Copyright © Central Institute for Experimental Animals